Medical device maker Dexcom on Thursday reiterated its full-year revenue forecast after beating Wall Street estimates for ...

DexCom (NASDAQ: DXCM) held its first-quarter earnings conference call on Thursday. Below is the complete transcript from the ...

DexCom Inc (DXCM) reports a robust 15% revenue increase, driven by international demand and strategic product launches, despite challenges in the US market.

ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD. VANCOUVER, BC, April 29, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – There's a quiet bidding war underway for AI diagnostics, and the price ...

Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the ...

Intuitive Surgical faces mixed international trends as China pressure and Japan delays cloud otherwise strong OUS growth ...

DexCom, Inc. DXCM reported first-quarter 2026 adjusted earnings per share (EPS) of 56 cents, which beat the Zacks Consensus ...

Small internal tears in Omnipod 5 insulin pump pods could lead to underdosing ...

In terms of stakeholders revenue share in 2022, the Mobile Operators and Device Vendors segments represented more than ...

B.C. has gone from one of the worst public formularies to what I consider to be one of the best. So how did we get here?

Our evidence guide separates real nano-enabled biohacking from marketing claims, from glucose sensors and nanoformulations to ...

Q1 2026 earnings call: 15% revenue growth, Prime coverage expansion, G7 15 Day rollout, and raised margin outlook.